Patheon has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its facility in Milton Park, UK.
The Xcelodose 600 S Automated Encapsulator supports early phase development for oral dose products.
The technology adds to on-site services, from early development to life cycle management of both small and large molecules, as well as enhances Patheon’s Quick to Clinic capabilities.
Xcelodose 600 S manufactures active pharmaceutical ingredients (API) in capsule form for Phase I through to pilot-scale Phase II clinical trials.
The technology fills API directly into the capsules, with no requirement of excipients, and can save up to six months of development time by reducing the need for formulation development and stability testing.
Xcelodose technology offers precision at filling speeds of more than 600 capsules per hour, and is ten times faster than manual filling methods.
Milton Park manager of formulation Dr Jon Sutch said: "With this new technology, we can bring medications to trial more quickly for our customers."
Patheon’s Milton Park facility focuses on the development and formulation of semi-solid, oral liquid and solid dosage forms at the earliest development phases, and aims to bring projects to clinical trials as quickly as possible.